Ionis Pharmaceuticals (NASDAQ:IONS) Announces Earnings Results

Ionis Pharmaceuticals (NASDAQ:IONS) posted its quarterly earnings results on Wednesday. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.12) by $0.46, RTT News reports. The company had revenue of $227.00 million for the quarter, compared to analyst estimates of $140.97 million. Ionis Pharmaceuticals had a negative net margin of 64.25% and a negative return on equity of 111.15%. The business’s quarterly revenue was down 30.2% on a year-over-year basis. During the same period last year, the business posted $0.12 EPS. Ionis Pharmaceuticals updated its FY 2025 guidance to EPS.

Ionis Pharmaceuticals Stock Down 0.4 %

IONS opened at $32.55 on Friday. The company has a market cap of $5.14 billion, a PE ratio of -10.75 and a beta of 0.34. The company has a 50 day moving average of $33.73 and a 200 day moving average of $38.46. Ionis Pharmaceuticals has a 12 month low of $30.23 and a 12 month high of $52.34. The company has a current ratio of 8.91, a quick ratio of 8.82 and a debt-to-equity ratio of 1.86.

Insider Transactions at Ionis Pharmaceuticals

In related news, EVP Patrick R. O’neil sold 6,165 shares of the stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $31.62, for a total transaction of $194,937.30. Following the sale, the executive vice president now owns 57,452 shares of the company’s stock, valued at approximately $1,816,632.24. This represents a 9.69 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Brett P. Monia sold 38,843 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $31.65, for a total value of $1,229,380.95. Following the transaction, the chief executive officer now directly owns 180,683 shares of the company’s stock, valued at $5,718,616.95. The trade was a 17.69 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 110,609 shares of company stock valued at $3,564,867 over the last three months. Company insiders own 2.71% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Piper Sandler cut their target price on Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. StockNews.com lowered shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th. William Blair reaffirmed an “outperform” rating on shares of Ionis Pharmaceuticals in a research note on Friday, December 20th. Needham & Company LLC reissued a “buy” rating and set a $60.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday. Finally, Wells Fargo & Company dropped their price objective on Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating for the company in a report on Thursday, November 7th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Ionis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $60.00.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.